Fc Protein and Glycoengineered Antibodies Market Size Estimation, Top Key Players and Future Trends | Kyowa Hakko Kirin Co. Ltd., Merck KGaA, Boehringer Ingelheim International GmbH
Monoclonal antibodies are developed by identical immune cells, which have a therapeutic use. The crystallized fragments (Fc) protein and glycoengineered antibodies are known as the next generation antibodies. These monoclonal antibodies are immunoglobulin G (IgG) type of molecules, which are attached to a glycan residue on crystallisable fragment. Glycoengineering is the method by which these antibodies are created. They have varied applications for the treatment of diseases such as multiple sclerosis and cancers.
Get FREE Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables and Figures) of Fc Protein and Glycoengineered Antibodies Market, https://www.coherentmarketinsights.com/insight/request-sample/2626
Global Fc Protein and Glycoengineered Antibodies Market Drivers
Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period.
For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth.
Increasing prevalence of diseases such as cancer is expected to propel the global Fc protein and glycoengineered antibodies market growth. According to the World Health Organization (WHO), cancer is considered as the second most leading cause of death worldwide, and, in 2018, around 9.6 million people died worldwide due to cancer. Hence, glycoengineered antibodies can be developed for the treatment of cancer and thus, this factor is expected to drive growth of the global fc protein and glycoengineered antibodies market over the forecast period.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2626
Global Fc Protein and Glycoengineered Antibodies Market Restraints
High cost of drugs is expected to hinder the global Fc protein and glycoengineered antibodies market growth. Manufacturers are focused on offering a highly effective drug, thus investing more into research and development activities. This increases the final cost price of the product. According to Pharmacy and Healthcare Communication, LLC, Gazyva costs around US$ 41,300 for six months treatment of cancer. Hence, this factor is expected to restrain growth of the global fc protein and glycoengineered antibodies market.
Global Fc Protein and Glycoengineered Antibodies Market Regional Analysis
North America region is expected to dominate in the global fc protein and glycoengineered antibodies market due to factors such as product launches, presence of leading manufacturers (such as F. Hoffmann La-Roche Ltd.), and active research and development in the field. Drugs such as Obinutuzumab (Gazyva), Mogamulizumab (Poteligeo), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi) have been approved in the U.S. in 2013, 2018, 2016, and 2017 respectively.
Europe is expected to witness significant growth in the global Fc protein and glycoengineered antibodies market. Factors such as approval for new drugs is expected to drive the Europe’s Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2018, Kyowa Hakko Kirin Co. Ltd. received an approval from the European Commission to market the Poteligeo antibody in the European market. It is the first biological product that is being directed against chemokine receptor 4 (CCR4), which will be used for the treatment of Sezary syndrome that has been previously treated by systemic therapy. Such new drug approvals are expected to propel Europe Fc protein and glycoengineered antibodies market growth over the forecast period.
Got any Query? Feel free to ask us at https://www.coherentmarketinsights.com/insight/talk-to-analyst/2626
Global Fc Protein and Glycoengineered Antibodies Market Key Players
Some of the major players operating in the global Fc protein and glycoengineered antibodies market include Kyowa Hakko Kirin Co. Ltd., Merck KGaA, Boehringer Ingelheim International GmbH, AstraZeneca Plc, Amgen Inc., Genentech Inc., Five Prime Therapeutics Inc., Celldex Therapeutics, Clovis Oncology, and TG Therapeutics, Inc.
Global Fc Protein and Glycoengineered Antibodies Market Taxonomy
The global Fc protein and glycoengineered antibodies market is segmented on the basis of drug, application, and region.
- Approved Drugs
- Obinutuzumab (Gazyva)
- Mogamulizumab (Poteligeo)
- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Pipeline Drugs
- Autoimmune Disease
- North America
- Latin America
- Asia Pacific
- Middle East
Other Related Reports:
Prepacked Chromatography Columns Market, By Product Type (1–100 mL, 100–1000 mL, >1L), By Technique (Hydrophobic Stationary Phase, Ion Exchange Chromatography, Affinity Chromatography, Multimodal Chromatography, Gel Filtration, Others), By Application (Sample Preparation, Resin Screening, Protein Purification, Anion and Cation Exchange, Desalting), By End User (Pharmaceutical Biotechnology, Food and Beverage, Agriculture and Environmental, Nutraceutical, Academics and Research, Analytical laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Cell and Tissue Culture Supplies Market, By Product Type (Consumables Products (Media (Classical Media, Lysogeny Broth, Chemically Defined Media, Specialty Media, Serum Free Media, Protein Free Media), Reagents (Growth Factors & Cytokines, Albumin, Amino Acids, Thrombin, Protease Inhibitors, Others), Sera (Fetal Bovine Serum, Others), Contamination Detection Kits, Cryoprotective Agents), Instruments (Culture Systems, Biosafety Cabinets, Incubators, Cryostorage Equipment’s, Roller Bottle Equipment’s, Pipetting Instruments, Others)), By Application (Biopharmaceutical Production, Vaccine Production, Drug Screening & Development, Gene Therapy, Toxicity Testing, Cancer Research, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire